Rennova Health(RNVA)
$0.000.00 (0.00%)
RNVA
Rennova Health financials statements
$0.00
At close:0.00 (0.00%)
Rennova Health (RNVA) Ratios
224 Followers
Rennova Health Ratios
RNVA's free cash flow for Q4 2023 was $258.02K. For the 2023 fiscal year, RNVA's free cash flow was decreased by $-27.41K and operating cash flow was $285.42K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.16 | 0.13 | 0.10 | 0.05 | 0.06 |
| Quick Ratio | 0.16 | 0.12 | 0.10 | 0.04 | 0.06 |
| Cash Ratio | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
| Solvency Ratio | -0.13 | -0.06 | 0.13 | -0.29 | -0.57 |
| Operating Cash Flow Ratio | 0.08 | -0.00 | -0.19 | -0.29 | -0.16 |
| Short-Term Operating Cash Flow Coverage | 1.06 | -0.02 | -0.59 | -0.86 | -0.27 |
| Net Current Asset Value | $ -50.15M | $ -43.30M | $ -42.22M | $ -58.56M | $ -78.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.58 | 0.73 | 0.82 | 1.80 | 3.41 |
| Debt-to-Equity Ratio | -0.32 | -0.52 | -0.59 | -0.45 | -0.73 |
| Debt-to-Capital Ratio | -0.47 | -1.08 | -1.43 | -0.82 | -2.69 |
| Long-Term Debt-to-Capital Ratio | -0.29 | 0.00 | 0.00 | -0.03 | 0.00 |
| Financial Leverage Ratio | -0.55 | -0.71 | -0.72 | -0.25 | -0.21 |
| Debt Service Coverage Ratio | 0.26 | -0.04 | -0.08 | -0.24 | -0.33 |
| Interest Coverage Ratio | 0.94 | -0.62 | -3.93 | -1.75 | -0.72 |
| Debt to Market Cap | 3.48 | 1454.59 | 273845.53 | 528.52 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 35.09 | 10620.58 | 0.00 |
| Net Debt to EBITDA | 8.09 | -47.11 | -12.14 | -2.62 | -2.09 |
| Profitability Margins | |||||
| Gross Profit Margin | 59.46% | 48.08% | -64.16% | -63.66% | 2.81% |
| EBIT Margin | 6.09% | -5.98% | -59.15% | -126.54% | -155.30% |
| EBITDA Margin | 7.76% | -2.38% | -39.19% | -116.81% | -150.33% |
| Operating Profit Margin | 7.31% | -10.81% | -388.37% | -238.82% | -98.10% |
| Pretax Profit Margin | -1.68% | -23.30% | -157.97% | -263.22% | -291.08% |
| Net Profit Margin | -41.36% | -25.26% | 173.86% | -254.71% | -300.15% |
| Continuous Operations Profit Margin | -2.96% | -25.70% | -163.54% | -245.05% | -291.08% |
| Net Income Per EBT | 2461.17% | 108.43% | -110.06% | 96.77% | 103.11% |
| EBT Per EBIT | -22.99% | 215.46% | 40.68% | 110.22% | 296.72% |
| Return on Assets (ROA) | -38.16% | -16.01% | 28.55% | -149.56% | -326.59% |
| Return on Equity (ROE) | 20.99% | 11.32% | -20.53% | 37.41% | 69.75% |
| Return on Capital Employed (ROCE) | -6.14% | 4.91% | 46.85% | 36.65% | 22.85% |
| Return on Invested Capital (ROIC) | -7.24% | 10.08% | 111.37% | 59.47% | 84.63% |
| Return on Tangible Assets | -38.66% | -16.21% | 28.93% | -152.80% | -338.31% |
| Earnings Yield | -235.46% | -32956.13% | 10221356.84% | -46666.09% | 0.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.81 | 2.41 | 0.90 | 3.75 | 3.80 |
| Payables Turnover | 0.61 | 0.60 | 0.44 | 0.83 | 1.19 |
| Inventory Turnover | 38.23 | 27.89 | 18.87 | 26.46 | 25.32 |
| Fixed Asset Turnover | 3.99 | 2.73 | 0.59 | 0.82 | 1.92 |
| Asset Turnover | 0.92 | 0.63 | 0.16 | 0.59 | 1.09 |
| Working Capital Turnover Ratio | -0.48 | -0.31 | -0.07 | -0.11 | -0.27 |
| Cash Conversion Cycle | -456.65 | -439.82 | -410.79 | -330.34 | -196.66 |
| Days of Sales Outstanding | 129.96 | 151.35 | 406.79 | 97.32 | 95.97 |
| Days of Inventory Outstanding | 9.55 | 13.09 | 19.35 | 13.80 | 14.42 |
| Days of Payables Outstanding | 596.16 | 604.26 | 836.92 | 441.46 | 307.05 |
| Operating Cycle | 139.51 | 164.44 | 426.13 | 111.11 | 110.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.00 | -0.00 | -16.25 | -5642.79 | 0.00 |
| Free Cash Flow Per Share | 0.00 | -0.00 | -16.25 | -5766.42 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 9.65 | -6.20 | 0.00 | -45.64 | -108232.36 |
| Capital Expenditure Coverage Ratio | 9.65 | -6.20 | 0.00 | -45.64 | -108232.36 |
| Operating Cash Flow Coverage Ratio | 0.29 | -0.01 | -0.56 | -0.77 | -0.27 |
| Operating Cash Flow to Sales Ratio | 0.18 | -0.02 | -2.76 | -2.35 | -0.85 |
| Free Cash Flow Yield | 92.52% | -2537.75% | -16252837.01% | -44018.49% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.42 | -0.00 | 0.00 | -0.00 | 0.00 |
| Price-to-Sales (P/S) Ratio | 0.18 | 0.00 | 0.00 | 0.01 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.09 | -0.00 | -0.00 | -0.00 | 0.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 1.08 | -0.04 | -0.00 | -0.00 | 0.00 |
| Price-to-Operating Cash Flow Ratio | 0.97 | -0.05 | -0.00 | -0.00 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | 10.36 | -47.14 | -12.14 | -2.62 | -2.09 |
| Enterprise Value | 15.01M | 14.62M | 15.33M | 22.03M | 50.20M |
| EV to EBITDA | 10.36 | -47.14 | -12.14 | -2.62 | -2.09 |
| EV to Sales | 0.80 | 1.12 | 4.76 | 3.06 | 3.14 |
| EV to Free Cash Flow | 4.94 | -57.65 | -1.72 | -1.27 | -3.71 |
| EV to Operating Cash Flow | 4.43 | -66.95 | -1.72 | -1.30 | -3.71 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -50.26 | -16425.73 | 0.00 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 | -49.79 | -16339.25 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.76 | -0.10 | -0.04 | 0.07 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 5.88 | 2400.04 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | 10.22 | -6113.26 | 0.00 |
| Tax Burden | 24.61 | 1.08 | -1.10 | 0.97 | 1.03 |
| Interest Burden | -0.28 | 3.90 | 2.67 | 2.08 | 1.87 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.50 | 0.55 | 2.33 | 1.62 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -6.12 | 0.07 | 1.69 | 0.96 | 0.29 |
Currency in USD
